259809-67-1

Upstream product

• 132629-37-9 ethyl 2-[(E)-2-phenylethenyl]oxazole-4-carboxylate 

Downstream Products

• 296795-18-1 (3R)-3-hydroxy-3-(2-((E)-2-phenyl-1-ethenyl)-1,3-oxazol-4-yl)-thiopropionic acid S-tert-butyl ester 
• 259809-68-2 2-[(E)-2-Phenylethenyl]-4-vinyloxazole 
• 296795-34-1 (3R)-3-(2-((E)-2-phenyl-1-etheny)-1,3-oxazol-4-yl)-3-(triethylsilyloxy)thiopropionic acid S-tert-butyl ester 
• 1027560-84-4 3-[2-(1,2-dihydroxy-2-phenyl-ethyl)-oxazol-4-yl]-3-triethylsilanyloxy-thiopropionic acid S-tert-butyl ester 
• 296795-41-0 (2R,6S)-2-(benzyloxymethyl)-6-(((2R,4S,6R)-4-(triisopropylsilyloxy)-6-(2-(triisopropylsilyloxy)methyl-1,3-oxazol-4-yl)tetrahydro-2H-pyran-2-yl)-methyl)-tetrahydro-4H-pyran-4-one 
• 296795-25-0 N-phenyl 4-((2R,6R)-4-methylene-6-(((2R,4S,6R)-4-(triisopropylsilyloxy)-6-(2-(methanesulfonylmethyl)-1,3-oxazol-4-yl)tetrahydro-2H-pyran-2-yl)methyl)tetrahydro-2H-pyran-2-yl)but-2-ynamide 
• 296795-21-6 4-((2R,4S,6R)-6-(((7S,9R)-9-(benzyloxymethyl)-1,4,8-trioxaspiro-[4.5]dec-7-yl)methyl)-4-(triisopropylsilyloxy)tetrahydro-2H-pyran-2-yl)-2-(triisopropylsilyloxymethyl)-1,3-oxazole 
• 296795-20-5 (4R,6R)-1-((7S,9R)-9-(benzyloxymethyl)-1,4,8-trioxa-spiro[4.5]dec-7-yl)-4-hydroxy-6-(triethylsilyloxy)-6-(2-(triisopropylsilyloxymethyl)-1,3-oxazol-4-yl)-hexan-2-one 
• 296795-13-6 4-((2R,4R,6R)-6-(((7S,9R)-9-(benzyloxymethyl)-1,4,8-trioxaspiro[4.5]dec-7-yl)methyl)-6-hydroxy-4-(triisopropylsilyloxy)tetrahydro-2H-pyran-2-yl)-2-(triisopropylsilyloxymethyl)-1,3-oxazole 
• 296795-24-9 N-phenyl 4-((2R,6R)-4-methylene-6-(((2R,4S,6R)-4-(triisopropylsilyloxy)-6-(2-(triisopropyloxy)methyl-1,3-oxazol-4-yl)tetrahydro-2H-pyran-2-yl)methyl)tetrahydro-2H-pyran-2-yl)but-2-yn-amide 
• 296795-36-3 (4R,6R)-1-((7S,9R)-9-(benzyloxymethyl)-1,4,8-trioxa-spiro[4.5]dec-7-yl)-6-(triethylsilyloxy)-4-(triisopropylsilyloxy)-6-(2-(triisopropylsilyloxymethyl)-1,3-oxazol-4-yl)hexan-2-one 
• 296795-37-4 N-phenyl 4-((2R,6R)-4-methylene-6-(((2R,4S,6R)-4-(triisopropylsilyloxy)-6-(2-(hydroxymethyl)-1,3-oxazol-4-yl)tetrahydro-2H-pyran-2-yl)methyl)tetrahydro-2H-pyran-2-yl)but-2-ynamide 
• 259809-70-6 2-(2-{2-[(E)-2-Phenylethenyl]oxazol-4-yl}ethyl)-1H-isoindol-1,3(2H)-dione 
• 259809-72-8 5-(tert-butoxycarbonyl)-2-(trans-β-styryl)-4,5,6,7-tetrahydrooxazolo[5,4-c]pyridine 

Relevant academic research and scientific papers

DIAMINE DERIVATIVES

A compound represented by formula (1):Q1-Q2-To-N(R1) -Q3-N(R2)-T1-Q4 [wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 represents the following group: (wherein Q5 is an alkylene group having 1 to 8 carbon atoms, or the like); and T0 and T1 are carbonyl groups or the like], a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

Diamine derivatives

A compound represented by the general formula (1): Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4??(1) wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

NOVEL ETHYLENEDIAMINE DERIVATIVES

A compound represented by the following formula (1):Q-Q-T-N(R)-Q-N(R)-T-Q [wherein, R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may have a substituent, or the like; Q2 is a single bond or the like; Q3 represents the following group: -C(R3a)(R4a)-{C(R3b)(R4b)}m1-{C(R3c)(R4c)}m2-{C(R3d)(R4d)}m3-{C(R3e)(R4e)}m4-C(R3f)(R4f)- (in which, R3a to R4e represent hydrogen or the like); T0 represents a carbonyl group or the like; and T1 represents -COCONR- or the like]; or salt thereof, solvate thereof, or N-oxide thereof. The compound is useful as a preventive and/or therapeutic agent for cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

DIAMINE DERIVATIVES

A compound represented by the general formula (1):Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4 wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

Application of complex aldol reactions to the total synthesis of phorboxazole B

The synthesis of phorboxazole B has been accomplished in 27 linear steps and an overall yield of 12.6%. The absolute stereochemistry of the C4-C12, C33-C38, and C13-C19 fragments was established utilizing catalytic asymmetric aldol methodology, while the absolute stereochemistry of the C20-C32 fragment was derived from an auxiliary-based asymmetric aldol reaction. All remaining chirality was incorporated through internal asymmetric induction, with the exception of the C43 stereocenter which was derived from (R)-trityl glycidol. Key fragment couplings include a stereoselective double stereodifferentiating aldol reaction, a metalated oxazole alkylation, an oxazole-stabilized Wittig olefination, and a chelation-controlled addition of the fully elaborated alkenyl metal side chain.